August 19 - 20, 2010, The Hilton San Diego Resort & Spa, San Diego, CA
Register by June 25, 2010 and receive up to $400 off!
Download the Brochure
Podcast
Pharma IQ is joined by Mark Divers, Executive Director, KI Biobank at Karolinska Institute, to discuss some of the prevalent aspects in the growing field of biobanking, from international partnerships to standardizing protocol.
Become a Pharma IQ Member and receive our weekly newsletter!
Learn more about sponsor & exhibit opportunities
Mark Your Calendar
Tell a Colleague
(Separate registration is required)
Currently, when it comes to large biorepository initiatives, there are a few biobanks that have hundreds of thousands of participant samples with related health histories and information. In some cases specific clinic goals are set at 100+ donors per day. When sample processing efforts in the tens of thousands are taken into account budgets become a challenge to manage.
What will be covered:
How you will benefit:
Mark G. Mense DVM, PhD, MBA, Diplomate, ACVP, ABT, Head, Global Pathology Translational Sciences-Research MedImmune, LLC
Access to high quality samples is considered as the main bottleneck for scientific communities focused on research. Health organizations and biobanks are the most adequate bodies to try to resolve this issue. However, biobanking is not a static activity, and so veterans and newcomers alike must continually engage in communication and networking. To accomplish current requirements of the scientific community biobanks need to face some essential challenges as a collective body, including appropriate design of biorepositories, harmonized and more suitable procedures, and sustainability. All of these goals must be accomplished with keen consideration of ethic, legal and social challenges. Discussion questions for the attending include:
Liz Horn Director Genetic Alliance
Progress in the field of pharmacogenomics is expected to impact the future of biobanks significantly. Pharmacogenetic research is seeking to identify genetic markers that account for the diversity in efficacy and adverse effects of particular drugs in different patient groups. The concept of better aiding physicians in matching drugs and dosages to individual patients is hard to turn one’s back on. Topics to be discussed include:
Sandra Close Kirkwood Research Technologies and Experimental Medicine Eli Lilly
The Roswell Park Cancer Institute (RPCI) is America's first cancer center, founded in 1898 by Dr. Roswell Park. It is the only upstate New York facility to hold the National Cancer Center designation of "comprehensive cancer center" and to serve as a member of the National Comprehensive Cancer Network. Within the center, the Roswell Park Data Bank and BioRepository (DBBR) conducts translational and medical research by using biospecimens from patients and healthy controls. Topics to be discussed include:
Mary Nesline Co-Director Roswell Park Data Bank and Biorepository
Private self funded Biobanks occupy an important niche in a space dominated by large players who often have access to public financing and links to academics and other respected experts. In order to be successful, smaller private biobanks have to be innovative, nimble and flexible. With the relatively small number of available patients and samples, as well as limited access to funding, sub-standard collection management is not an option. It is counter productive for scientists to perform expensive analyses on poor-quality samples. Thus appropriate clinical protocol and database design as well as pre-analytics are essential components in all collections. The opportunity to pre-determine these essential components in prospective studies is extremely useful. Join this interactive session and learn about the following:
John Flax PresidentPrecisionMed
Karine Sargsyan DirectorSecretariat Biobank Medical University of Graz
During the past 10 years, human biological material—body fluids, cells, tissues, intracellular substances or DNA—and the related data have become an important resource for academic medical research, and for the industrial development of diagnostics and therapeutics. The increasing creation and use of biobanks that store both the material and the related data bears witness to their scientific value, but there is still no consensus— either internationally, or at the European or national levels— about the regulations that should govern biobanks in ethical or legal terms. In particular, consent models designed to appropriately regulate biobank-based research are characterized by a maze of laws, policies and ethical recommendations that range from strict (specific informed consent) to basically unrestricted use. Topics to be discussed include:
Anne Bahr Deputy R&D Data Privacy Officer Sanofi-Aventis
Leading technology experts will bring us through current advances in preparation, application, and leveraging of biospecimens for patient populations. Beginning first with a summary of innovation trends, the discussion continues from view of advances in population-based health studies to reaching the patient’s bedside through translational medicine. Topics to be discussed include:
Session Chairperson:
Rhett Affleck Vice President of Technology Nexus Biosystems
Panelists:
Edward P. Frantz Jr. National Sales DirectorEnvironmental Specialties
Ellis Gitlin Director of SalesHamilton Storage Technologies
“Bio”-transportation Takes on a New Meaning as the BioBanking Event’s Audience Heads to the Shore PrecisionMed Inc., founded in 1994, is a privately held human biobank in Solana Beach. The executive management team is clearing room in the corporate calendar to host a guided tour of their facility. Introductions to the specialized neurobiology repository will be made and participants are encouraged to open up discussions specific to equipment and the biobanking business model supported by PrecisionMed.
First come first served seating offered to all individuals registering for the pre-conference Workshop!
[ Register Now ]